Tim Smith

This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.

These findings suggest the need for additional clinical evaluations in trials on a larger scale to allow for confirmation of the efficacy and safety of the treatment.

This new data may help to indicate a potential common immunological mechanism, allowing for greater assessment of the effects of therapeutic agents and treatment combinations.

These new findings represent the only PTC case to look at such a unique number of concurrent comorbidities in current medical literature.

These phase 2 data indicate that the implant may be a helpful addition to clinicians’ interventional glaucoma armamentarium for patients.

During this interview, Perkins described a recent landmark study which yielded some unique findings regarding pathogen-detection.

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

This new data align with the acknowledged necessity for a disruption of the itch–scratch cycle in moderate-to-severe AD treatment among patients.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

The Dermatology Month in Review for dermatology features 2 interviews, findings from recent long-term data, and a discussion of the FDA’s approval of secukinumab for HS.

In this retrospective review of medical charts, trends in systemic treatment use among psoriasis patients in Japan pointed to several notable findings.

This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.

These pivotal trial results from a study in China indicated the potential of this drug as a quarterly treatment for individuals with eczema.

This phase 3 program was advised to discontinue given that cobitolimod was shown to be less likely to meet its primary endpoint.

In this interview, Dr. Chovatiya summarized and discussed the updated National Psoriasis Foundation consensus statements for GPP.

This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.

This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.

This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.

This new data may help health policymakers to better strategize their approaches to management of childrens’ nutritional anemias.